InvestorsHub Logo
Followers 617
Posts 94614
Boards Moderated 12
Alias Born 11/01/2006

Re: None

Monday, 08/22/2016 1:50:08 PM

Monday, August 22, 2016 1:50:08 PM

Post# of 20669
Would anyone want to try and make sense of the numbers thrown around in this release given the current SS?

Inolife Technologies has entered into a definitive merger agreement with 8687544 Canada Inc., the definitive merger agreement has been amended as an definitive asset purchase agreement and the number of shares increase from 30,000,000 common shares post reverse split of 1 for 30,000 to 50,000,000 common shares post reverse split of 1 for 30,000.

Inolife Technologies has not been able to obtain approval from FINRA after its second attempt to cure deficiencies. Inolife Technologies will cure its deficiencies at the New York State filings and said deficiencies may take up to 8 weeks to cure.

The parties have agreed to close the asset purchase agreement prior to the reverse split being approved and effective by FINRA. Inolife Technologies has agreed to issue 10,000,000 Preferred
Series B of Inolife Technologies to N3GU Capital Ltd., and said Preferred shares Series B shall be returned to treasury and cancelled upon the effectiveness of the reverse split of 1 for 30,000 and the issuance and receipt of 50,000,000 common shares in the name of N3GU Capital Ltd. and or its nominee. Further to the business combination, a change of directors and officer is required. The new name for the Corporation shall be Inolife Sciences Inc.

You can lead a horse to water. But you can't make him get down on one knee and do an Al Jolson impression!